[go: up one dir, main page]

Dore et al., 2002 - Google Patents

39 PA novel monoclonal antibody test to detect H. pylori antigens in human stool

Dore et al., 2002

Document ID
6359031596172154786
Author
Dore M
Negrini R
Marras L
Tadeu V
Simula L
Cherchi G
Osato M
Graham D
Realdi G
Publication year
Publication venue
Digestive and Liver Disease

External Links

Continue reading at scholar.google.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication Publication Date Title
Scarpellini et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome: a preliminary study.
Peterson et al. Clarithromycin as Monotherapy for Eradication of Helicobacter pylori. A Randomized Double-blind Trial
Cremonini et al. Effect of Different Probiotic Preparations on Anti-Helicobacter PyloriTherapy-Related Side Effects: A Parallel Group, Triple Blind, Placebo-Controlled Study
Fiorini et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection
JP5027512B2 (en) Immunomodulation
de Boer et al. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study
Raja Lambert-Eaton myasthenic syndrome and botulism
JP2005526861A (en) Manipulation of gastrointestinal transport rate by regulating intestinal methane concentration
Xia et al. Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients
Karczewska et al. Levofloxacin resistance of" Helicobacter pylori" strains isolated from patients in Southern Poland between 2006-2012
Williams et al. Seven‐day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride
Dore et al. 39 PA novel monoclonal antibody test to detect H. pylori antigens in human stool
Festa et al. 40 P Levofloxacin based triple therapy as second-line treatment for H. pylori infection after failure of standard triple therapy
Di Caro et al. 37 P Use of 10 days levofloxacin-based triple therapy in second-line treatment for H. pylori eradication: A new strategy
Gatta et al. 38 P Metronidazole susceptibility testing by agar dilution, epsilometer test (E-test) and disk diffusion in helicobacter pylori (HP) strains
Raina et al. Efficacy of levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOAD) regimen compared with standard triple therapy to eradicate Helicobacter pylori infection: a prospective randomized study from a tertiary hospital in India
Bolton et al. Clostridium difficile in toxic megacolon complicating acute inflammatory bowel disease
JP3680950B2 (en) Uses of allylamine
Sides Clinical efficacy of dirithromycin in acute exacerbations of chronic bronchitis
Aguemon et al. Primary antibiotic resistance and effectiveness of Helicobacter pylori triple therapy in ulceroinflammatory pathologies of the upper digestive tract
Giannini et al. Influence ofHelicobacter PyloriEradication Therapy on 13C Aminopyrine Breath Test: Comparison Among Omeprazole-, Lansoprazole-, Or Pantoprazole-Containing Regimens
Mantzaris et al. Prospective, randomized study of seven versus fourteen days omeprazole quadruple therapy for eradication of Helicobacterpylori infection in patients with duodenal ulcer after failure of omeprazole triple therapy
Rasul et al. The Diagnosis of Common Variable Immunodeficiency After Multisystem Dysfunction
Jiang et al. Small-cell lung cancer presenting with Lambert-Eaton myasthenic syndrome and respiratory failure
Kuwayama et al. Comparison of standard dose rabeprazole and double dose omepazole in PPI-bassed triple therapy for Helicobacter pylori infection-a randomized clinical trial